Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cannabinoids in glaucoma: a primary screening procedure.

M A Elsohly, E Harland, J C Murphy

    Journal of Clinical Pharmacology
    |August 1, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Design, synthesis, molecular modeling and anti-proliferative evaluation of novel quinoxaline derivatives as potential DNA intercalators and topoisomerase II inhibitors.

    European journal of medicinal chemistry·2018
    Same author

    Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of novel quinoxaline derivatives as potential PPARγ and SUR agonists.

    Bioorganic & medicinal chemistry·2017
    Same author

    Health behaviours associated with indoor tanning based on the 2012/13 Manitoba Youth Health Survey.

    Health promotion and chronic disease prevention in Canada : research, policy and practice·2016
    Same author

    Morphine and Codeine in Biological Fluids: Approaches to Source Differentiation.

    Forensic science review·2015
    Same author

    Cost benefit for assessment of intermediate coronary stenosis with fractional flow reserve in public and private sectors in australia.

    Heart, lung & circulation·2014
    Same author

    Optical coherence tomography (OCT) as an adjunct to percutaneous coronary intervention; a single centre experience.

    International journal of cardiology·2012
    Same journal

    FDA Gene Therapy Approvals (1998-2025): Current Status, Regulatory Evolution, and Future Directions.

    Journal of clinical pharmacology·2026
    Same journal

    Human Disposition, Metabolism, and Excretion of Sevasemten (EDG-5506), a Selective Modulator of Fast Myosin in Healthy Volunteers.

    Journal of clinical pharmacology·2026
    Same journal

    New Insights into Genetic Polymorphisms Influencing the Therapeutic Efficacy and Toxicity of Rivaroxaban.

    Journal of clinical pharmacology·2026
    Same journal

    Physiologically Based Pharmacokinetic Modeling to Predict the Pharmacokinetics of Sacubitril/Valsartan in the Elderly with Renal or Hepatic Impairment Population.

    Journal of clinical pharmacology·2026
    Same journal

    The Journal of Clinical Pharmacology: 65 Years of History.

    Journal of clinical pharmacology·2026
    Same journal

    Decoupling CAR-T Expansion, Conversion, and Decay Timing: Physiologically Aligned Semi-Mechanistic Modeling With Smooth Gating and a Cauchy Likelihood Residual Model.

    Journal of clinical pharmacology·2026
    See all related articles

    A new method screened cannabinoids for reducing intraocular pressure (IOP) in rabbits. Delta 8-THC, delta 9-THC, cannabinol, and nabilone effectively lowered IOP, while cannabidiol did not show activity.

    Area of Science:

    • Pharmacology
    • Ophthalmology
    • Cannabinoid Research

    Background:

    • Elevated intraocular pressure (IOP) is a significant risk factor for glaucoma.
    • Cannabinoids are being investigated for potential therapeutic applications in various medical conditions, including ocular diseases.
    • Existing research suggests some cannabinoids may possess ocular hypotensive properties, necessitating further investigation.

    Purpose of the Study:

    • To establish and validate a reliable procedure for screening cannabinoids' efficacy in reducing intraocular pressure (IOP).
    • To identify specific cannabinoids that demonstrate significant IOP-lowering effects in a preclinical model.
    • To compare the activity of various cannabinoids, including delta-8-THC, delta-9-THC, cannabinol, nabilone, and cannabidiol.

    Main Methods:

    Related Experiment Videos

    • Development of an in vivo screening procedure using normal rabbits.
    • Intravenous (I.V.) administration of test compounds and standardized positive (delta 9-THC) and negative controls.
    • Periodic intraocular pressure (IOP) measurements over a 5-hour period post-injection.
    • Statistical analysis of IOP data using a computer program accounting for control group variations.

    Main Results:

    • The developed procedure demonstrated statistical significance with eight animals per group.
    • Delta 8-THC, delta 9-THC, cannabinol, and nabilone were identified as active compounds, effectively reducing IOP.
    • Cannabidiol was found to be inactive in this screening model.

    Conclusions:

    • The established rabbit model provides a robust platform for evaluating the ocular hypotensive potential of cannabinoids.
    • Specific cannabinoids, including delta-8-THC, delta-9-THC, cannabinol, and nabilone, show promise for IOP reduction.
    • Further research into the therapeutic applications of these active cannabinoids for ocular conditions is warranted.